Notice ID: cba4ed3aabb64bb3b8570872b0c0c5f0Combined Synopsis/Solicitation
COVID-19 Wastewater Data Testing
Archived on October 20, 2020. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- Posted
- October 2, 2020
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- Small Business Set Aside - Total
- NAICS
- 541380: Testing Laboratories and Services
- Agency
- Department of Health and Human ServicesOFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA)
Notice details
- Office
- PROGRAM SUPPORT CENTER ACQ MGMT SVC
- Place of performance
- Washington, DC, 20001
- Last updated
- Sep 25, 2026
Identifiers
- Solicitation number
- 75P00120Q00176
- Notice ID
- cba4ed3aabb64bb3b8570872b0c0c5f0
Description
The Department of Health and Human Services (HHS) Office of the Chief Information Officer (OCIO) urgently requires the collection and analysis of wastewater samples to fight the COVID-19 pandemic and protect the public’s health. This data will be transferred into HHS Protect, the HHS COVID-19 Data Sharing Platform that ingests, integrates, manages, and analyzes HHS data sets, publicly available data sets, state and local data sets, and private sector data sets, providing a comprehensive view of all pertinent information in near real-time to make data-backed decisions. See solicitation attachments 75P00120Q00176 SF1449 and Continuation Pages.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Lashawn Haggins
Secondary Contact
Documents
No documents available.
Lifecycle
Solicitation:
75P00120Q00176- Combined Synopsis
- 6×Combined SynopsisCurrentSep 24, 2020
COVID-19 Wastewater Data Testing
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Amendment 2 - Review Amendment COMBINED SYNOPSIS / SOLICITATION (COMPETITIVE) Title: Senior Advisor Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise for the NINDS Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative for the Pain Therapeutics Development Program (PTDP) (i) This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with RFO Part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. The solicitation number is 7571PSQ00007 issued as a Request for Quote for a Senior Advisor to act as a Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise. The Government reserves the right to make one award, multiple awards, or no awards as a result of this solicitation. This acquisition is set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (ii) This requirement is for the following services: NINDS is seeking to procure a highly experienced executive-level, drug discovery and development Senior Advisor 2 with extensive expertise in drug discovery and development, in support of the NIH HEAL Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. (iii) Description of requirement: The NIH is seeking to procure a highly experienced executive-level Senior Advisor 2, drug discovery and development subject matter expert with experience in the area of Pharmacology and Pain to provide feedback to the NIH program leadership and technical guidance on drug discovery and development projects within the NINDS HEAL portfolio. The Contractor will serve as a member of the HEAL External Oversight Committee, which will provide strategic guidance on HEAL projects and on occasion other NIH drug discovery and development programs. See Attachment #1 - Statement of Work (SOW) for more information. (iv) The Government anticipates award of a Fixed Price purchase order for this acquisition, and the anticipated base period of performance is: Base: 11/5/2026 – 11/4/2027 Option Year 1: 11/5/2027 – 11/4/2028 Option Year 2: 11/5/2028 – 11/4/2029 (v) The provisions at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this address: https://www.acquisition.gov/far-overhaul https://www.hhs.gov/contract-policies-regulations/hhsar-overhaul (End of provision) a) The following FAR provisions are required by FAR 12.2025(a), and incorporated by reference: • FAR 52.212-1 (Nov 2025) (RFO Deviation), Instructions to Offerors-Commercial Products and Commercial Services. b) The following FAR provisions are required as applicable to this requirement and incorporated by reference: • See Attachment 2 for (Table # 12-2) under FAR 12.205 (a)(3). c) The following HHSAR provisions are applicable to this requirement and incorporated by reference (available upon request): • HHSAR 352.239.78 – Information and Communication Technology Accessibility Notice (FEB 2024) (Deviation) (vi) The clauses at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: https://www.acquisition.gov/far-overhaul https://www.hhs.gov/contract-policies-regulations/hhsar-overhaul (End of clause) a) The following FAR clauses are required by FAR 12.205(b)(1) for all solicitations and incorporated by reference: • FAR 52.212-4 (Nov 2025) (RFO Deviation), Terms and Conditions—Commercial Products and Commercial Services. b) The following FAR clauses are required as applicable to this requirement and incorporated by reference: • See Attachment 3: Table# 12-3. • FAR 52.232-39, Unenforceability of Unauthorized Obligations (Jun 2013). The following HHSAR clauses are applicable to this requirement and incorporated by reference: • HHSAR 352.204-71, Information and Information System Security (FEB 2024) (Deviation). • HSHAR 352-204-73 – Contractor Personnel Security and Agency Access (FEB 2024) (Deviation). • HHSAR 352-239-79 – Information and Communication Technology Accessibility (Feb 2024) (Deviation). FAR/HHSAR PROVISIONS/CLAUSES – FULL TEXT-ADDITIONAL TERMS AND CONDITIONS The following provisions/clauses and additional terms and conditions apply to this acquisition and are provided in FULL TEXT: a) HHSAR 352-237-75 Key Personnel (Oct 2026) (RFO Deviation) - Key personnel specified in this contract are essential to work performance under the contract. The Contractor must obtain the written consent of the Contracting Officer prior to diverting, replacing, or announcing any key personnel substitutions. At least 30 days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts, the Contractor must submit requests for changes in key personnel to the Contracting Officer in writing. The request must identify the circumstances, proposed replacement, a resume and explanation of how the replacement's skills, experience, and credentials meet or exceed the requirements of the contract. When advance notice is not practicable because of termination for cause, other voluntary separation or another circumstance outside the Contractor’s reasonable control, the Contractor must notify the Contracting Officer as soon as practicable. (End of clause) b) FAR 52.217-7, Option for Increased Quantity-Separately Priced Line Item (Mar 1989) The Government may require the delivery of the numbered line item, identified in the Schedule as an option item, in the quantity and at the price stated in the Schedule. The Contracting Officer may exercise the option by written notice to the Contractor within the period of performance of the contract. Delivery of added items shall continue at the same rate that like items are called for under the contract, unless the parties otherwise agree. (End of clause) c) 52.217-9 Option to Extend the Term of the Contract. (a) The Government may extend the term of this contract by written notice to the Contractor within 15 days of contract expiration; provided that the Government gives the Contractor a preliminary written notice of its intent to extend within the period of performance of the contract. The preliminary notice does not commit the Government to an extension. (b) If the Government exercises this option, the extended contract shall be considered to include this option clause. (c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 3 years. (End of clause) TECHNICAL EVALUATION AND INSTRUCTIONS The Government will evaluate quotations or offers in accordance with RFO FAR 12.203 and award a purchase order from this solicitation to the responsible vendor whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The factors included in Attachment 5 – Evaluation Factor--shall be used to evaluate quotes: a) Technical capability of the item offered to meet the Government requirement; b) Price; and c) Past performance [see RFO FAR 12.203(a)(2)]. Technical Requirements Instructions: Responses must include clear and convincing evidence of the Quoter’s capability of fulfilling the requirement as it relates to Technical Factor 1: Personnel Qualifications. These responses shall include resumes of proposed key personnel, consultants, and any subcontractors, as well as a letter of commitment from proposed key personnel. These responses should also clearly identify whether proposed personnel will be or are an employee of the Quoter. Please note that all proposed key personnel must be employed by the Quoter no later than the start of the contract’s period of performance. Please note, however, that while resumes of all proposed key personnel are required, they are NOT, by themselves, sufficient. Quoters MUST also submit a separate narrative demonstrating how proposed Key Personnel satisfy the Personnel Qualifications evaluation criteria. Please carefully examine the evaluation criteria prior to writing this narrative. Business Instructions: Quoters are required to complete Attachment 4 – Price Template. Quoters are only to fill in the highlighted cells (including the proposed labor rate and the number of consultants being proposed); all other cells will then auto-populate. Quoters must submit the completed pricing template in Excel (do not convert to PDF) as a separate attachment and shall not combine or embed the pricing template with other materials. Quoters will note that the Government anticipates estimated 50 labor hours per year, with an option for an up-to-additional 50 hours per year. It should also be noted that the Government may reimburse the successful Quoter(s) for up to $2,000 in annual travel-related expenses, per-consultant, that are necessary for performance of this requirement. These funds shall be provided only after it is determined there is a need for travel. Additionally, all travel requests require advance approval by the Government. If the Quoter proposes the involvement of any additional staff besides the Key Personnel, it must clearly articulate their role and why it believes additional personnel are necessary to fulfill the requirement. The Quoter must also specify how this time will be charged (e.g. direct hourly rate or included within overhead). Finally, the Quoter is required to document its rationale for any proposed Other Direct Costs (ODCs) besides travel as well as the total amount. If any of these conditions are applicable, the Quoter shall add rows for the additional costs to the Price Template and include a Price Narrative in its response. Salary Rate Limitation: Quoters are advised that no NIH funds may be used to pay the direct annual salary of an individual through any contract awarded as a result of this solicitation at a rate in excess of the Executive Schedule, Level II* (direct salary is exclusive of Overhead, Fringe Benefits and General and Administrative expenses, also referred to as "indirect cost" or "facilities and administrative (F&A) costs"). Direct salary has the same meaning as the term "institutional base salary." An individual's direct salary (or institutional base salary) is the annual compensation that the Quoter pays for an individual's appointment whether that individual's time is spent on research, teaching, patient care or other activities. Direct salary (or institutional base salary) excludes any income that an individual may be permitted to earn outside of duties to the Quoter. This does not preclude Quoters from absorbing that portion of an employee's annual salary (plus the dollar amount for fringe benefits and associated indirect costs) that exceeds a rate of the Executive Schedule, Level II*. The Executive Schedule, Level II* annual salary rate limitation also applies to individuals proposed under subcontracts as well as consultants. LINK TO EXECUTIVE SCHEDULE RATES OF PAY: https://www.opm.gov/policy-data-oversight/pay-leave/salaries-wages/ (For current year rates, click on Salaries and Wages/Executive Schedule/Rates of Pay for the Executive Schedule. For prior year rates, click on Salaries and Wages/select Another Year at the top of the page/Executive Schedule/Rates of Pay for the Executive Schedule. Rates are effective January 1 of each calendar year unless otherwise noted.) Past Performance: Quoter shall identify 1-2 awards with the Federal Government and/or commercial customers that demonstrate recent and relevant past performance. Relevant is defined as work similar in complexity and magnitude to the work described in the SOW. Quoter shall include the following information in their past performance examples: • Project title • Description of the project • Contract number • Contract amount • Government Agency/Organization • Point of contact name, address, and phone number • Contract and, if applicable, task order number • Current status, e.g., completed and/or if in progress, start and estimated completion dates • SOW paragraphs that the reference applies to • Key personnel (please highlight those individuals who worked on the relevant project(s) and are also being proposed for this effort.) • A brief narrative of why you deem the reference to be relevant to this effort Response Format: Quoter responses shall be no more than ten (10) single-sided pages in length. This page limit includes the following: (i) Cover Page, if applicable (ii) Executive Summary, if applicable (iii) Table of Contents, if applicable (iv) Key Personnel Narrative (no more than two pages) (v) Price Narrative, if applicable (vi) Past Performance Examples This page limit does NOT include: (i) Key Personnel Resume(s) (ii) Letter(s) of Commitment (iii) Representations and Certifications (iv) Completed Price Template Additional Required Information: In addition to the previously discussed requirements, Quoters must include the following in their response: 1) Company’s Full Name and Address 2) Unique Entity ID (UEI) 3) Name, Telephone Number, and Email Address of Person Authorized to Provide Quote Please note that, to be considered for award, Quoters must also be actively registered in the System for Award Management (SAM), accessible at www.sam.gov, at the time of quote submission. (a) Options - The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. The evaluation of options does not obligate the Government to exercise the option(s). (b) Notice of award. A written notice of award or acceptance of an offer furnished to the successful Offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (End of provision) The following invoice instruction is included and will be incorporated in the final award: • Agency Invoicing Instructions (Attachment 6, Invoice Instructions). (vii) Quoter must submit all required materials by 1:00 PM Eastern Time on November 2, 2026 (AMENDMENT 1) and reference solicitation number 7571PSQ00007 Responses must be submitted electronically to Michelle Cecilia, Contracting Officer, at michelle.cecilia@hhs.gov All questions must be received by October 27, at 1:00 p.m. EST in and reference Solicitation Number 7571PSQ00007. (viii) The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices. The associated NAICS code 541690 and the small business size standard is $19 million. FAR DEVIATION STATEMENT: “System updates may lag policy updates. The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in this solicitation. Contracting officers will rely on representations from offers based on provisions in the solicitation. Entities are not required to, nor are they able to, update their entity registration to remove these representations in SAM.” Responses to this solicitation must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal/quote must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. The Unique Entity ID (UEI) from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. | - | Combined Synopsis | 11/02/2026 |
The U.S. Department of Agriculture (USDA), Agricultural Marketing Service (AMS) is issuing Solicitation 12‑1NTS‑26‑R‑0002 to obtain proposals from responsible, accredited analytical laboratories to perform microbiological and fat testing in support of AMS meat, poultry, egg, and aquatic product procurement programs. This requirement establishes AMS Designated Laboratories (ADLs) responsible for conducting all required microbiological and chemical analyses on samples submitted by AMS vendors, ensuring compliance with Federal Purchase Program Specifications (FPPS) and supporting food safety and quality verification efforts. AMS intends to award an Indefinite Delivery/Indefinite Quantity (IDIQ) firm‑fixed‑price contract, consisting of a Base Period and up to four option periods, covering performance from April 1, 2027 through March 31, 2032. Offerors must be fully capable of meeting all technical, accreditation, reporting, and quality assurance requirements outlined in the Statement of Work (SOW) and must maintain ISO/IEC 17025 accreditation for all applicable microbiological and chemical test methods throughout the contract term. Offerors are required to submit a complete proposal package in accordance with Section E of the solicitation, including all technical, management, past performance, and pricing components, as well as a properly completed and signed SF‑1449. Offerors must ensure all requirements, instructions, and submission details—such as WBSCM electronic submission processes—are fully reviewed and followed. Incomplete proposals may not be considered for award. Key expectations under this solicitation include: • Performance of all required microbiological and fat analyses using approved methods (FSIS MLG, AOAC, AOCS, or AMS‑approved alternatives). • Comprehensive sample preparation, receipt, testing, reporting, and data management in accordance with AMS SOW requirements. • Timely reporting of results, including notification of presumptive or confirmed pathogen positives to AMS, FSIS, and vendors. • Secure handling and management of proprietary AMS data. • Full compliance with FAR, AGAR, and USDA‑specific contract clauses incorporated into the solicitation. Prospective offerors are strongly encouraged to read the entire solicitation package, including the SOW, exhibits, and all referenced clauses, to ensure a complete and conforming submission. | - | Solicitation | 11/20/2026 |
The National Highway Traffic Safety Administration (NHTSA) is issuing this Sources Sought Notice to identify potential qualified Small Business (SB), Small Disadvantaged Business (SDB), 8(a) Certified SDB, HUBZone SB, SDVOSB, or WOSB concerns that may be interested in and capable of performing the work described herein which is to provide Full Scale Vehicle Crashworthiness Testing and Side Air Bag Out-of-Position Testing for the New Car Assessment Program (NCAP). NHTSA welcomes all qualified Small Business concerns, with the appropriate NAICS Code and past experience to submit their Corporate Capability Statements that demonstrate their ability to successfully accomplish the goals of the project as listed below. NHTSA does not intend to award a contract on the basis of responses to this notice or otherwise pay for the preparation of any information submitted. Acknowledgement of receipt of responses will not be made; no formal evaluation of the information received will be conducted by NHTSA. NHTSA may; however later on issue a Request for Proposals (RFP). However, should such a requirement fail to materialize, no basis for claims against NHTSA shall arise as a result of a response to this notice. Background: The National Highway Traffic Safety Administration (NHTSA) is an agency of the U.S. Department of Transportation (DOT). NHTSA’s mission is to save lives, prevent injuries, and reduce traffic-related health care and other economic costs. The agency develops, promotes, and implements effective educational, engineering, and enforcement programs with the goal of ending vehicle crash tragedies and reducing economic costs associated with vehicle use and highway travel. As part of this work, NHTSA conducts a variety of motor vehicle crash tests including, but not limited to, frontal, rear, oblique, side moving deformable barrier (MDB), and side pole impact test modes. NHTSA also conducts various crash avoidance tests, static and dynamic rollover tests, air bag out-of-position low risk deployment tests, tire testing, and testing in accordance with Federal Motor Vehicle Safety Standards (FMVSS). To support future efforts, NHTSA expects to conduct research for future FMVSS, crash avoidance technologies, automated vehicles, and electric vehicles. The agency may also conduct testing to assess new crash test dummies and child restraint systems and may perform research study vehicle safety defects. The New Car Assessment Program (NCAP) is a consumer information program conducted by NHTSA. Its major goals are to: (1) provide consumers with relative safety ratings information to assist them in their vehicle purchasing decisions and (2) use market forces to motivate automobile manufacturers to design vehicles to a higher level of occupant protection. To accomplish these goals, NHTSA utilizes testing contracts to conduct NCAP testing and release test results to the public as quickly as possible so that consumers can use this information when selecting a new vehicle to purchase. The contractor shall support NHTSA’s testing/research efforts by providing inspection, testing, and reporting services for NCAP. Federal law requires new passenger vehicles to be labeled with NCAP safety ratings information published by NHTSA. The Contractor shall be responsible to include all the necessary equipment, personnel, facilities, and management of personnel and workflow as identified in the attached Draft Statement of Work (SOW). Any interested qualified Small Business firms, Small Disadvantaged Business (SDB), 8(a) Certified SDB, HUBZone SB, SDVOSB, or WOSB concerns should submit their Corporate Capability Statement, which demonstrates the firm’s ability and past experience in no more than 10 pages to perform the key requirements described above to the identified NHTSA point of contact listed herein. Any proprietary information should be marked as such. All respondents are asked to certify the type and size of their business organization is in-line with the requirements of this Sources Sought Notice which must be received no later than 10 calendar days from the date of publication or by the closing date of this notice. To facilitate a timely and comprehensive review of all submitted responses, firms should respond using the format requested in this Notice. Please provide the following information for your firm and for any teaming or joint venture partners: General Information Company name, address, point of contact name, telephone, and email address. Data Universal Numbering System (DUNS) Number and Commercial and Government Entity (CAGE) Code. Business size and classification (e.g., large, small, small-disadvantaged, SBA Certified 8(a), HUBZone, service-disabled veteran-owned, woman-owned) based on NAICS code: 541380, Testing Laboratories. If applicable, potential proposed teaming arrangements to include business size and classification of prime and subcontractors. GSA Federal Supply Schedule (FSS) Number (FSS must include NAICS code 541380, Testing Laboratories Identify contracts your company has been awarded under NAICS code: 541380, Testing Laboratories Technical Capability: Provide a brief synopsis to support the firm’s ability to perform all of potential areas of the objective/scope. Identify each task element and provide information to support the firm’s experience, staffing and overall ability to perform the technical area. Evidence of experience and past performance should include contracts/task orders from the past three (3) years similar in scope to this requirement. Examples must include contract numbers, project titles, dollar amounts, periods of performance, and Government points of contact (telephone numbers or email addresses). Documented information to support the firm’s ability to provide the range of research skillsets capability to quickly plan, conduct, and document studies; AND personnel required for this effort in a timely fashion. Any data on previous contracts/task orders on personnel retention and succession planning. Additional Information: Indicate if your firm will submit a proposal if a Request for Proposal (RFP) is issued, and if your firms interest is for Prime contracting, teaming agreement or Joint Venture. Validation of, or recommended NAICS codes for this effort. Validation of, or recommended contract type. Validation of, or recommended GSA vehicle In each potential areas of research, indicate any Small Business Subcontracting opportunities, as applicable. Other Recommendations Any information missing from this requirement that would provide a better understanding of the effort desired. Please submit any other questions or comments along with your response. CONTRACTING OFFICE ADDRESS Department of Transportation (DOT) Headquarters, 1200 New Jersey Avenue, SE, Washington, DC 20590. | - | Market Research | 11/02/2026 |
The National Highway Traffic Safety Administration (NHTSA) is an agency of the U.S. Department of Transportation (DOT). NHTSA’s mission is to save lives, prevent injuries, and reduce traffic-related health care and economic costs. The agency develops, promotes, and implements effective educational, engineering, and enforcement programs to reduce vehicle crash-related fatalities and injuries. The Electronic Systems Safety Division conducts research, testing, and analysis to evaluate how vehicle electronic subsystems impact vehicle safety and to identify countermeasures to mitigate safety risks. NHTSA’s research portfolio includes work related to Advanced Driver Assistance Systems (ADAS), Automated Driving Systems (ADS), and vehicle cybersecurity. These efforts aim to advance the safe development, testing, and deployment of vehicle safety technologies while addressing emerging risks such as driver distraction, system reliability, and cybersecurity vulnerabilities. This research complements efforts undertaken by industry, academia, and other government agencies and is intended to advance the state of knowledge and support data-driven safety decision-making. NHTSA with the capability to issue task orders requiring a wide range of research and technical support services related to vehicle safety technologies. Work under this contract may include: Planning, conducting, and documenting vehicle safety research studies •Testing and evaluation of ADAS and ADS technologies •Simulation and modeling of vehicle systems and driver behavior •Vehicle component testing and functional safety assessments •On-road testing and naturalistic driving studies •Safety impact assessments and data analysis •Cybersecurity research and evaluation •Application of artificial intelligence (AI) and machine learning (ML) to vehicle safety | - | Pre-Solicitation | 12/30/2026 |
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals from small business concerns (SBCs) that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward ARPA-H mission needs, Small Business Innovation Research (SBIR), and Small Business Technology Transfer (STTR) program objectives. Please see the cover page of the attachment "SBIR_STTR_BAA_FY26" for applicable Stage 1 and Stage 2 deadlines for each open topic. Please see the Attachment H "ARPA-H_SBP_Government_Answered_Questions" for responses to the Q&A period. The purposes of the SBIR and STTR programs are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR and STTR programs, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees. Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. AMENDMENT 01 - July 8, 2026: Amendment 01 of this solicitation extends the deadline for Stage 1 Solution Summaries from July 10, 2026 to July 17, 2026. This amendment answers conforming questions that were submitted prior to the Q&A deadline via Attachment H. This amendment adds/revises the following soliciation sections: Add change log, revise sections 2.3, 3.1, 3.2, 4.2, 4.3, 4.4, 5.0, 5.4, add section 5.5, revise section 8, topic 6, and topic 7. AMENDMENT 02 - August 17, 2026: Amendment 02 of this solicitation publishes the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following sections: cover page, 2.2, 2.3, 2.4, 2.6, 2.8, and 8. Amendment 02 corresponds with Stage 1 encourage/discourage letter distribution for topics 01, 02, 03, 04, 06, and 07. Please check your email inbox for your Stage 1 encourage/discourage letters on or around August 17, 2026. Topic 05 Stage 1 letters and Stage 2 submission deadline will be distributed at a later date. AMENDMENT 03 - September 1, 2026: Amendment 03 of this solicitation publishes the Stage 2 submission deadline for Topic 05. This amendment revises language in the following sections: cover page and 8. Amendment 03 corresponds with Stage 1 encourage/discourage letter distribution for topic 05. Please check your email inbox for your Stage 1 encourage/discourage letters on or around September 1, 2026. Amendment 03 updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 04 - September 10 2026: Amendment 04 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 05 - September 11 2026: Amendment 05 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. This amendment also unprotects Attachment B Cost Proposal Spreadsheet and updates the instructions sheet. THE FOLLOWING ARE THE CURRENTLY OPEN RESEARCH TOPICS. PLEASE SEE SECTION 8 OF THE BAA FOR FURTHER INFORMATION ARPA-H 01 - Development of an annual test to inform women about their future fertility - The purpose of this topic is to discover new biomarkers that provide women with actionable data for fertility planning. Results from this work will help inform the program manager regarding the feasibility of future programs focused on enhancing natural fertility before the need of IVF and guiding the development of women’s health monitoring and improvement tools. This work will develop a diagnostic test that can assess fertility status and generate an estimated timeline for the onset of infertility. This topic seeks to develop a test that is affordable, suitable for at least annual use, and provides user-friendly results for patients and care teams to support childbearing decisions. ARPA-H 02 - Versatile Bioadhesives - The purpose of this topic is to develop next-generation bioadhesive platforms that can safely and reliably seal, bond, and repair a wide range of tissues in challenging clinical conditions, including wet, bloody, and mechanically dynamic environments. These platforms may also be designed to deliver biologics or small molecules as part of treatment. The goal is to create bioadhesives with key performance attributes such as strong tissue adhesion, controlled degradation, reversibility, biocompatibility, and broad compatibility across multiple tissues and organs. If successful, this topic could enable widely deployable solutions for hemostasis, leak prevention, tissue repair, and device fixation, ultimately helping reduce complications and improve patient outcomes across many care settings ARPA-H 03 - Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT) - The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case. ARPA-H 04 - Breaking Ground: The First Curative, Durable, Non-Surgical Therapy for Endometriosis – The purpose of this topic aims to develop treatments for endometriosis that are non-surgical. Proposers are expected to develop novel, non-surgical therapies to decrease the size or deactivate endometrial implants, to decrease inflammation cause by implants, and / or prevent growth or regrowth of the lesions. Broadly, this should be a novel, non-surgical, curative treatment for endometriosis. ARPA-H 05 - ARPA-H Lineage Topic - The purpose of this topic supports the advancement, commercialization, and translation of technologies that originated from ARPA-H funded efforts. It is intended to help small businesses and startups develop viable products based on these technologies. ARPA-H’s goal is to give small businesses an off-ramp to finish developing their technology/product, explore secondary or interim applications of the technology, and time to achieve self-sufficiency. ARPA-H 06 - Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease -The purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care physicians to diagnose and predict tissue-specific autoimmune disease manifestations, thereby streamlining referral of the patient to a specialist. This goal is made more feasible by recent technological developments including the ability to detect tissue-specific signatures of immune-mediated stress by assessing circulating cells and/or tissue-specific molecular products. ARPA-H 07 - Virtual Human Brain for the Development of Neurosurgical Robotics - The purpose of this topic aims to take a first step toward AI-assisted intracranial microsurgery by creating a high-resolution, physically and anatomically accurate virtual human brain. | - | Pre-Solicitation | 10/01/2026 |
Additional Details
Solicitation Number
75P00120Q00176
Archive Date
Oct 20, 2020
Office Address
ROCKVILLE, MD, 20857